Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01688921 · ClinicalTrials.gov registry record · Phase 4
Jet Injection for Influenza
A Phase 4 study, sponsored by PharmaJet.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,250
- Enrollment target
NCT01688921 is a Phase 4 study that has completed, run by PharmaJet. The registered enrollment target is 1,250 participants.
The verdict
NCT01688921, a Phase 4 study, has completed, sponsored by PharmaJet.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,250 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the administration of a seasonal flu vaccine using a PharmaJet's needle-free injection device (STRATIS) is equivalent to needle and syringe administration, as measured by laboratory tests of immune response.
Interventions
- BIOLOGICAL AFLURIA vaccine (2012-2013 formulation)
- DEVICE Needle-Syringe
- DEVICE Stratis needle-free injection device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01688921
The ClinicalTrials.gov registry entry for NCT01688921 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaJet, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AFLURIA vaccine (2012-2013 formulation) is the first listed.
NCT01688921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01688921 about?
NCT01688921 is a clinical study titled "Jet Injection for Influenza". The purpose of this study is to determine if the administration of a seasonal flu vaccine using a PharmaJet's needle-free injection device (STRATIS) is equivalent to needle and syringe administration, as measured by laboratory tests of immune response.
What is the current status of trial NCT01688921?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,250 participants. The study started on 2012-10. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01688921?
The interventions under investigation include: AFLURIA vaccine (2012-2013 formulation) (BIOLOGICAL), Needle-Syringe (DEVICE), Stratis needle-free injection device (DEVICE).
Who is sponsoring clinical trial NCT01688921?
This trial is sponsored by PharmaJet, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.